High to moderate certainty in the body of evidence suggests that LGG supplementation ( regardless of the timing of administration ) did not reduce the risk of eczema .
There was also no consistent effect on other allergic outcomes .
This meta- analysis shows that LGG was ineffective in reducing eczema .
Current guidelines recommend the use of probiotics to reduce the risk of  eczema .
It remains unclear which strain(s ) to use .
We systematic ally evaluated data on the efficacy of Lactobacillus rhamnosus GG ( LGG ) supplementation prenatally and /or postnatally for the primary prevention of eczema .
Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial
In this r and omized controlled trial , we examined the effect of early LGG infant supplementation in decreasing the risk of childhood eczema .  OBJECTIVES : To determine if probiotic administration during the first 6 months of life decreases  childhood asthma and eczema . METHODS : We conducted a r and omized , double-blind controlled trial of Lactobacillus rhamnosus GG ( LGG ) supplementation on the cumulative incidence of eczema ( primary end point ) and  asthma and rhinitis  ( secondary end points ) in high-risk infants . For the first 6 months of life , intervention infants ( n = 92 ) received a daily dose of 10 billion colony-forming units of LGG and 225 mg of inulin ( Amerifit Br and s , Cromwell , CT ) , and control infants ( n = 92 ) received 325 mg of inulin alone . We used survival analysis methods to estimate disease incidences in the presence or absence of LGG and to estimate the efficacy of LGG in delaying or preventing these diseases . RESULTS : Infants were accrued over a 6-year period ( median follow-up : 4.6 years ; 95 % retention rate at 2 years ) . At 2 years of age , the estimated cumulative incidence of eczema was 30.9 % ( 95 % confidence interval [ CI ] , 21.4%–40.4 % ) in the control arm and 28.7 % ( 95 % CI , 19.4%–38.0 % ) in the LGG arm , for a hazard ratio of 0.95 ( 95 % CI , 0.59–1.53 ) ( log-rank P = .83 ) . At 5 years of age , the cumulative incidence of asthma was 17.4 % ( 95 % CI , 7.6%–27.1 % ) in the control arm and 9.7 % ( 95 % CI , 2.7%–16.6 % ) in the LGG arm , for a hazard ratio of 0.88 ( 95 % CI , 0.41–1.87 ) ( log-rank P = .25 ) . CONCLUSIONS : For high-risk infants , early LGG supplementation for the first 6 months of life does not appear to prevent the development of eczema or asthma at 2 years of age
High to moderate certainty in the body of evidence suggests that LGG supplementation ( regardless of the timing of administration ) did not reduce the risk of eczema .
There was also no consistent effect on other allergic outcomes .
This meta- analysis shows that LGG was ineffective in reducing eczema .
Current guidelines recommend the use of probiotics to reduce the risk of  eczema .
It remains unclear which strain(s ) to use .
We systematic ally evaluated data on the efficacy of Lactobacillus rhamnosus GG ( LGG ) supplementation prenatally and /or postnatally for the primary prevention of eczema .